What Sarcoma Follow-Up Involves: Scheduled Imaging, Wound Review and Function Checks

The stitches are out, the pathology report has been explained twice, and the surgeon has just said the words most people wait weeks to hear: the margins were clear. Then comes the sentence nobody rehearses for. “We’ll see you in three months, with a scan.” Three months. The number lands somewhere between reassurance and a trapdoor.

Almost everyone treated for a soft tissue sarcoma reaches this moment, and almost everyone leaves the room with the same unspoken question: what, exactly, is going to happen at all those appointments? A printed sarcoma follow up imaging schedule rarely says why the chest is scanned when the tumor was in a thigh, why the same nurse keeps measuring the calf, or why the physiotherapist wants to watch you climb a step.

This explainer walks through the three strands that make up sarcoma surveillance, scans, wound review and function checks, what the evidence behind each one actually shows, and where it is honest to say the evidence runs thin.

What does a sarcoma follow-up imaging schedule usually look like?

Start with the honest part. The most widely used European guideline for soft tissue sarcoma states plainly that no published trial has shown one surveillance schedule to be better than another. The schedules below are expert consensus built on how these tumors behave, not the product of a head-to-head study (ESMO-EURACAN-GENTURIS guideline, PubMed).

A sarcoma is a cancer that starts in connective tissue such as muscle, fat, blood vessels or nerve sheath. Grade describes how abnormal the cells look under the microscope and how quickly they are dividing, and grade is the single biggest driver of how often follow-up happens.

Tumor grade	Years 1 to 2–3	To year 5	After year 5	What is usually imaged
High or intermediate grade	Every 3–4 months	Every 6 months	Once a year	Chest CT or X-ray; MRI or ultrasound of the operated area
Low grade	Every 4–6 months for 3–5 years	Every 4–6 months	Once a year	Chest X-ray or CT at longer intervals; local imaging as needed

Source for intervals: ESMO-EURACAN-GENTURIS guideline (PubMed reference below). Your own team may lengthen or shorten these gaps based on subtype, site, margins and how you are recovering.

Two things stand out in that table. First, the intensity is front-loaded, because most recurrences appear in the first two to three years after treatment (same guideline). Second, follow-up does not stop at year five; it thins out to an annual check, since some subtypes relapse late.

Notice also what the table does not contain: routine blood tests or whole-body scans. For most soft tissue sarcomas, neither has been shown to catch recurrence earlier than a physical exam plus targeted imaging.

How sarcoma follow-up works: what actually happens at each visit

A follow-up visit is less dramatic than the countdown to it. Most appointments follow a predictable rhythm, and knowing the rhythm removes a good deal of the dread.

The scan usually comes first, sometimes a few days before the appointment so the report is ready. If your schedule includes a chest CT, you lie on a table that slides through a ring-shaped scanner; the pictures take minutes, though the visit may run longer if contrast dye is given through a vein. A chest X-ray is quicker still. MRI, which uses magnets rather than radiation to picture soft tissue, takes longer and is noisier, and the operated limb or trunk is positioned inside a coil to sharpen the image.

Then the consultation. Expect three things in roughly this order:

• A conversation about how you have been: pain, new lumps, breathlessness, cough, weight, sleep, mood, work.
• A hands-on examination of the scar and surrounding tissue, the nearest lymph nodes, and the chest.
• A review of the images, ideally side by side with the previous set, because change over time matters more than any single picture.

Function checks may be woven into the same visit or handled separately by a physiotherapist or occupational therapist: range of movement measured with a goniometer (a hinged protractor for joints), limb circumference recorded with a tape, grip or leg strength, walking pattern, and how you manage stairs or overhead reach.

Finally, the plan. You should leave knowing when the next scan is, which type, and who to contact in between if something changes (NHS; Mayo Clinic).

Why the chest is scanned: where sarcoma recurrence after surgery tends to appear

People are often puzzled that a tumor removed from an arm or thigh is followed with pictures of the lungs. The explanation is anatomical. Soft tissue sarcomas spread mainly through the bloodstream rather than the lymph system, and the first capillary bed that circulating cells meet after leaving a limb is in the lungs. The lungs are therefore the most common site of distant relapse for sarcomas of the limbs and trunk wall (ESMO-EURACAN-GENTURIS guideline).

Recurrence, in plain terms, means the cancer has come back after treatment. It can be local, in or near the original site, or distant, in another organ. Both matter, but they are found differently: local recurrence is often felt as a new lump or picked up on MRI or ultrasound, while lung recurrence is usually silent until it is large, which is precisely why it is imaged on a schedule rather than waited for.

Which chest test? The guideline accepts either chest CT or plain X-ray. CT finds smaller nodules; X-ray involves far less radiation and is cheaper for health systems. Many teams use CT during the highest-risk early years and switch to X-ray later, or choose CT for high-grade tumors and X-ray for low-grade ones. The choice is a judgment call about your individual risk, and a reasonable question to ask your team is which one they have chosen for you and why.

Not every sarcoma follows the lung pattern. Some subtypes, discussed later, head for the abdomen, spine or soft tissues elsewhere, and the imaging plan shifts accordingly (Cleveland Clinic; Mayo Clinic).

MRI, ultrasound or CT: which scan checks the operated area?

The place the tumor was removed is called the tumor bed or surgical bed. Checking it is the second half of imaging surveillance, and the tool depends on where the tumor was and how deep.

MRI is the workhorse for limbs and trunk wall. It separates scar, fluid and muscle from the kind of solid tissue that might be regrowth, and it does so without radiation. Its weakness is that early after surgery and radiotherapy, the operated area looks busy: swelling, seroma (a pocket of clear fluid under the wound), inflammation and healing scar can all mimic or hide a small recurrence. For that reason many teams obtain a baseline MRI some weeks to months after treatment so later scans have something stable to compare against (ESMO-EURACAN-GENTURIS guideline).

Ultrasound is quick, radiation-free and good at superficial sites, and some centers use it for shallow tumors or between MRIs. Its accuracy depends heavily on the person holding the probe, and it cannot see deep into large muscle groups.

CT of the local site is used mainly when the tumor was in the abdomen or retroperitoneum (the space behind the abdominal lining), where CT with contrast outlines organs and vessels well and doubles as the chest and abdominal check in one visit.

Physical examination remains part of local surveillance for a simple reason: a superficial recurrence is often felt before it is imaged. Teams sometimes teach patients to examine the scar region themselves between visits, not as a diagnostic tool, but as a prompt to call early (NHS).

None of these scans is perfect, and a report that says “post-surgical change, recommend interval follow-up” is common and usually reassuring rather than alarming.

Who is followed closely, and who is usually asked to wait between scans

Surveillance is not one-size-fits-all, and teams sort people mainly by how likely recurrence is. The factors are well established (ESMO-EURACAN-GENTURIS guideline; Mayo Clinic):

• Grade: high-grade tumors relapse more often and earlier.
• Size: larger tumors, particularly above about 5 cm, carry more risk, which is also the size threshold used in urgent referral advice (NHS).
• Depth: tumors beneath the deep fascia (the tough sheet wrapping muscles) behave more aggressively than superficial ones.
• Margins: whether a rim of healthy tissue surrounded the removed tumor.
• Subtype: dozens of distinct sarcomas exist, with different habits.

Someone with a large, deep, high-grade tumor will typically be on the three-to-four-monthly track with chest CT. Someone with a small, superficial, low-grade tumor removed with clear margins may be seen every four to six months with a chest X-ray, and may be asked to wait longer between local scans.

“Asked to wait” can feel like being taken less seriously. It is the opposite. Scanning a low-risk person every three months exposes them to radiation, false alarms and repeated anxiety for little chance of finding anything, and guideline authors are explicit that the intensity of follow-up should scale with risk.

Age, other illnesses and kidney function also shape choices; contrast dye for CT, for instance, is used more cautiously when kidneys are impaired. Pregnancy shifts the balance toward MRI and ultrasound. Where a person lives and how easily they can travel to a specialist unit is a legitimate practical factor, and many teams arrange local imaging with specialist review of the pictures.

The decision about which track you are on belongs to your multidisciplinary team, and it can change as years pass without recurrence.

Wound review after sarcoma surgery and radiotherapy: what the team is looking at

Sarcoma wounds are not ordinary wounds. The operations are often long incisions through muscle, sometimes with skin grafts or a flap (tissue moved from elsewhere to close the gap), and many people also receive radiotherapy before or after surgery. Radiotherapy given before surgery is associated with a higher rate of early wound complications, while radiotherapy given afterward tends to cause more long-term stiffness and fibrosis, meaning thickened, less elastic scar tissue (ESMO-EURACAN-GENTURIS guideline). Either way, the wound earns its own line on the follow-up plan.

At the early visits the team looks for:

• Separation of the wound edges, called dehiscence.
• Signs of infection: spreading redness, warmth, pus, fever.
• Seroma or hematoma (fluid or blood collecting under the skin), which can delay healing or need draining.
• Graft or flap health, judged by color, temperature and capillary refill.

Later visits shift to the long game. Irradiated skin can thin, darken and lose hair; small dilated vessels called telangiectasia may appear; the underlying tissue can tighten over months. These changes are usually cosmetic or mildly uncomfortable, but they matter for function, and they can make the area harder to examine and image, which is another reason a baseline MRI is valuable.

Wound review also feeds the imaging schedule. A wound that has not fully healed may postpone the start of radiotherapy or the first MRI. A stubborn seroma may be watched on ultrasound rather than MRI for a while.

Practical care between visits is simple: keep the area clean, protect irradiated skin from sun, avoid tight straps or seams across the scar, and moisturize once the surface has closed, using whatever the team has advised (NHS; Cleveland Clinic).

Function checks: strength, movement, swelling and nerves

A sarcoma team measures success in two currencies: whether the cancer stays away, and whether the limb or body region still does its job. The second currency is easy to overlook when scan results dominate the conversation, yet it shapes daily life far more.

Function checks target four areas (Mayo Clinic; MedlinePlus):

• Range of movement at the nearest joints, because scar and radiotherapy shrink tissue over time and a joint that loses a few degrees a month can quietly become a contracture, a fixed shortening that resists stretching.
• Strength, since muscle removed with the tumor does not grow back and neighboring muscles must be trained to compensate.
• Swelling, particularly lymphedema, a persistent build-up of lymph fluid that can follow node removal or radiotherapy. Limb circumference is measured at set points and compared with the other side and with earlier visits.
• Nerve function: numbness, tingling, weakness or altered sensation, which can reflect nerve stretching at surgery, scar entrapment or, rarely, regrowth pressing on a nerve.

Timing matters. Rehabilitation usually starts early, sometimes within days of surgery for gentle movement, and continues alongside radiotherapy. Radiotherapy-related stiffness tends to develop gradually over the first year or two, so function checks are not a one-off; they are repeated at the same visits as the scans.

There is a bonus. A new loss of movement, new swelling or new pain that does not fit the healing pattern is itself a reason to look harder at the local site. Function checks are, in effect, a low-technology surveillance tool.

If you have not been offered a physiotherapy or occupational therapy plan, ask. Home exercise programs, compression garments for lymphedema and splints for contractures are all standard supportive measures, chosen and adjusted by your team.

What the first weeks and months after treatment usually look like

Timelines vary with the size of the operation and whether radiotherapy or chemotherapy is involved, so treat the following as a typical shape rather than a schedule (NHS; Mayo Clinic; ESMO-EURACAN-GENTURIS guideline).

The first two weeks are about the wound and mobility. Drains, if any, come out. Dressings are changed. Someone checks that you can walk, or grip, or reach, and that pain is controlled enough to move. Clot prevention, meaning early walking and sometimes injections or compression stockings arranged by the team, is part of this phase for limb and pelvic surgery.

Weeks two to six bring the results conversation, if it has not already happened: final grade, margins and subtype, which together determine your surveillance track. Radiotherapy planning may begin once the wound is sound. Physiotherapy intensifies.

Months two to four often include the first scheduled imaging: a baseline MRI of the operated area and the first chest check. Expect the MRI report to describe post-operative change; that is normal at this stage.

Months four to twelve settle into the rhythm of the table earlier in this article. Radiotherapy skin reactions fade, energy usually returns in steps rather than a straight line, and many people are back at work or study in modified form, depending on the job.

Year one onward is where late effects show themselves: stiffness, lymphedema, bone fragility in irradiated areas. It is also where the calendar starts to feel less like a threat and more like a routine.

Across all of this, one principle holds: the plan is revisited at every visit, and anything unexpected between visits is a reason to contact the team rather than wait for the next date.

What is the 2 week rule for sarcoma, and does it apply after diagnosis?

People searching for the 2 week rule for sarcoma are usually thinking of the referral pathway used in the UK’s health service, in which a family doctor who suspects cancer arranges for the person to be seen or scanned by a specialist within two weeks. For soft tissue lumps, the features that trigger this urgent route are well described: a lump that is growing, larger than about 5 cm, painful, deep to the muscle layer, or one that has come back after previous removal (NHS).

The rule is a triage tool for diagnosis. It is not a follow-up schedule, and it does not mean that a sarcoma spreads in two weeks or that a two-week delay changes the outlook. It exists because sarcomas are rare, roughly 1 percent of adult cancers (Cleveland Clinic), and because lumps are common, so a clear, fast pathway helps the uncommon dangerous lump get to the right hands quickly.

Does the spirit of the rule apply after treatment? In a practical sense, yes. Once you are under surveillance, a new lump near the scar, a new persistent cough or a new swelling should prompt an early call to the sarcoma team rather than a wait for the next scheduled appointment, and most specialist units run a nurse-led contact line for exactly this purpose. The team may bring your scan forward, add an ultrasound, or simply examine you and reassure.

What the rule does not mean is that every ache needs an urgent visit. Part of good follow-up is learning, with your team’s help, the difference between healing pain that eases with time and a new problem that persists or grows. The next sections and the red-flag list at the end are meant to help draw that line.

Leiomyosarcoma follow up guidelines and other subtype differences

Leiomyosarcoma is a sarcoma arising from smooth muscle, the involuntary muscle found in blood vessel walls, the uterus and the gut. It is one of the more common adult subtypes and a frequent source of the question “what is the recommended follow-up for leiomyosarcoma?”

The short answer is that it follows the same grade-based framework as other soft tissue sarcomas, with adjustments for where it started (ESMO-EURACAN-GENTURIS guideline):

• Limb or trunk leiomyosarcoma: chest imaging plus local MRI, on the high-grade track in most cases, since many are intermediate or high grade.
• Uterine leiomyosarcoma: chest imaging plus CT or MRI of the abdomen and pelvis, because relapse can occur in the pelvis, peritoneum and liver as well as the lungs.
• Retroperitoneal or vascular leiomyosarcoma: CT of chest, abdomen and pelvis together, as the local site and the likely metastatic sites overlap.

Other subtypes bend the schedule in their own ways. Myxoid liposarcoma, a fat-cell sarcoma, has an unusual tendency to spread to the spine, abdomen and soft tissues rather than the lungs, so guideline authors suggest considering abdominal or spinal MRI, or whole-body MRI, in its surveillance. Low-grade fibromyxoid sarcoma and some other indolent tumors can relapse many years later, which supports continuing annual visits beyond year five. Rhabdomyosarcoma, more common in children, and bone sarcomas such as osteosarcoma follow separate protocols that include lung CT but differ in local imaging.

Gastrointestinal stromal tumor, often grouped with sarcomas, is a special case with its own risk tables based on size, site and cell division count, and its follow-up leans on abdominal CT rather than chest imaging.

The message for any subtype is the same: ask your team what your particular tumor tends to do, because that behavior, not a generic calendar, is what shapes your scan list (Mayo Clinic; Cleveland Clinic).

How fast does sarcoma spread, and how often is it misdiagnosed?

Two of the most searched sarcoma questions have uncomfortable answers, because the honest reply is “it depends” for the first and “nobody has a reliable number” for the second.

Speed. Soft tissue sarcomas range from tumors that enlarge visibly over weeks to tumors that sit unchanged for years. Grade is the best guide: high-grade tumors divide rapidly and are more likely to have already seeded the bloodstream by the time they are found, which is why their follow-up is most intense in the first two to three years; low-grade tumors grow slowly and relapse later, if at all (ESMO-EURACAN-GENTURIS guideline). A rapidly enlarging lump is one of the features that triggers urgent referral (NHS). What no source can offer is a per-week growth rate for an individual person, and any article that gives one is guessing.

Misdiagnosis. Because sarcomas are rare and lumps are common, an early sarcoma is frequently first assumed to be something benign such as a lipoma (a fatty lump), a cyst, a hematoma after a knock, or a sports injury; many people report a delay between first noticing a lump and receiving the diagnosis (NHS; Mayo Clinic). Published estimates of how often this happens vary widely with the definition used and the health system studied, so this article does not quote a single figure. What the evidence does support is the remedy: imaging before any attempt to remove an unexplained deep or growing lump, and biopsy planned by a specialist team so that the needle track can be removed with the tumor.

After treatment, the practical lesson is symmetrical. New findings in a person with a sarcoma history should be looked at with a lower threshold than in the general population, which is exactly what a surveillance program formalizes.

Scan anxiety, radiation and the case for not over-scanning

If more scans meant more safety, the guideline would say so. It does not, and understanding why helps make peace with the gaps between appointments.

Radiation is the first reason. A chest CT delivers considerably more ionizing radiation than a plain chest X-ray, and over five years of three-monthly scans the total adds up, which is why guideline authors mention radiation exposure as a factor when choosing between the two and suggest that low-grade tumors, in particular, may be followed with X-ray (ESMO-EURACAN-GENTURIS guideline). MRI and ultrasound involve no ionizing radiation, which is one reason they are preferred for the local site.

False positives are the second. Every scan finds something in some people: a tiny lung nodule that turns out to be an old infection scar, a fluid pocket in the operated area, a lymph node at the upper limit of normal. Each finding can trigger an extra scan, a biopsy, or weeks of worry. The more often you image, the more of these you generate.

The third reason is the least discussed: for many people, the fortnight before each scan is the worst part of survivorship. Psychologists call it scan anxiety, and it is common enough that specialist units routinely offer support. Useful, evidence-based habits include booking the results appointment close to the scan, bringing someone, writing questions down beforehand, and telling the team if the anxiety is spilling into sleep or work (Mayo Clinic; MedlinePlus).

None of this argues for less follow-up than your risk warrants. It argues for follow-up matched to risk, which is precisely what a graded schedule tries to deliver. If you are on a lighter track, that is a reflection of your tumor’s behavior, not of anyone paying less attention.

What people often get wrong about sarcoma follow-up

Some misunderstandings surface at almost every clinic. Correcting them early saves worry.

“A clear scan means the cancer is gone.” A clear scan means nothing large enough to see is present today. Surveillance continues because microscopic disease can exist below the resolution of any scanner, and because behavior over time is more informative than one image (ESMO-EURACAN-GENTURIS guideline).

“The chest scan is a mistake; my tumor was in my leg.” As explained earlier, the lungs are the most common site of distant relapse for limb sarcomas, so the chest is the most useful place to look.

“Blood tests will show if it comes back.” Unlike some cancers, most soft tissue sarcomas have no reliable blood marker. Routine bloods are not part of standard surveillance, though your team may order them for other reasons, such as monitoring after chemotherapy.

“PET scans are better, so I should ask for one.” PET, which images sugar uptake by cells, has a role in specific situations, such as clarifying an ambiguous finding, but it is not a routine surveillance tool in the guideline and it carries its own radiation and false-positive burden.

“If I feel fine, I can skip a visit.” Lung recurrence is usually silent until advanced. Feeling well is welcome but not informative.

“After five years I am discharged.” Follow-up thins out; it rarely ends abruptly, because late relapse occurs in some subtypes.

“Pain at the scar means recurrence.” Scar tissue, nerve regrowth and radiotherapy changes cause pain for months and sometimes years. Pain that is new, progressive or accompanied by a lump deserves a call; familiar aching that fluctuates usually does not (NHS; Cleveland Clinic).

“Rehabilitation is optional.” Function lost to stiffness or lymphedema is far easier to prevent than to reverse.

Questions to ask your care team

Consultations are short and memory under stress is unreliable, so it helps to arrive with questions written down. These are the ones sarcoma teams most often wish people had asked earlier (drawn from NHS and Mayo Clinic patient guidance and the ESMO-EURACAN-GENTURIS surveillance recommendations).

About your risk and schedule:

• What was my tumor’s grade, size, depth and subtype, and which follow-up track does that put me on?
• How often will I have chest imaging, and will it be CT or X-ray? What would change that choice?
• When is my baseline MRI, and how often will the local site be imaged after that?
• Are there sites other than the lungs that my subtype tends to spread to, and are they covered?
• At what point, if ever, would the interval between scans lengthen?

About the wound and function:

• What should the scar look like at each stage, and what would be abnormal?
• Am I at risk of lymphedema, and should I be measured or fitted for a garment?
• Which exercises should I be doing now, and who will review them?
• Are there movements or activities I should avoid, and for how long?

About logistics and support:

• Who do I call between appointments, and how quickly can I expect a reply?
• Can imaging be done nearer home with the pictures reviewed by the specialist team?
• Is there psychological support for scan-related anxiety?
• Should my family doctor be doing anything differently, for example about other screening?

Writing the answers down, or asking permission to record the conversation, turns a blur of information into a plan you can actually follow. Decisions about scans, treatment and rehabilitation rest with your treating team; your job is to understand them well enough to take part.

When to call your doctor

Scheduled visits exist to catch what you cannot feel. The list below covers what you can feel, and what should prompt a call to your sarcoma team or family doctor before the next appointment rather than after it (NHS; Mayo Clinic; MedlinePlus).

Contact the team promptly for:

• A new lump or firm area at or near the scar, or anywhere else, especially one that is growing.
• A persistent new cough lasting more than a few weeks, coughing up blood, breathlessness that is new or worsening, or chest pain.
• Wound changes: edges opening, spreading redness or warmth, pus, an unpleasant smell, or a fever.
• Sudden swelling, pain or warmth in a calf or arm, which can signal a blood clot, or sudden breathlessness with chest pain, which can signal a clot in the lung.
• New numbness, tingling or weakness in the treated limb.
• Pain that is new, steadily worsening, wakes you at night or does not ease with rest and simple measures your team has advised.
• Unexplained weight loss, persistent nausea, abdominal swelling or a change in bowel habit, particularly after abdominal or uterine sarcoma.
• A rapid increase in limb swelling that compression and elevation do not settle.

Seek emergency care immediately for severe breathlessness, chest pain, coughing up significant blood, a wound bleeding heavily, or a limb that becomes suddenly cold, pale or numb.

Calling early is not overreacting. Most calls end in reassurance or a brought-forward scan that turns out normal, and specialist units plan for exactly that. The people who do best in follow-up are not the ones who never worry; they are the ones who know what to watch for, keep their scheduled visits, and treat the contact number as part of their care rather than a last resort. Every decision that follows a call, from an extra ultrasound to a biopsy, sits with your treating team.

Frequently asked questions

What is the 2 week rule for sarcoma?

It is a referral pathway in which a family doctor who suspects cancer arranges a specialist appointment or scan within two weeks. For soft tissue lumps, features that trigger it include a lump that is growing, larger than about 5 cm, painful, deep beneath the muscle layer, or recurring after removal (NHS). The rule speeds up diagnosis; it is not a follow-up schedule and does not describe how quickly a sarcoma spreads.

What is the recommended follow-up for leiomyosarcoma?

Leiomyosarcoma follows the general grade-based framework, usually the high-grade track: chest imaging plus local MRI roughly every 3–4 months for the first 2–3 years, then less often (ESMO-EURACAN-GENTURIS guideline). Uterine and retroperitoneal leiomyosarcoma add CT or MRI of the abdomen and pelvis because relapse can occur there. Your team adjusts intervals to your tumor’s site, grade and margins.

How often is sarcoma misdiagnosed?

No reliable single figure exists, because published estimates vary widely with how misdiagnosis is defined and where the study was done. What is well documented is the pattern: early sarcomas are frequently assumed to be benign lumps such as lipomas, cysts or hematomas, and many people describe a delay before diagnosis (NHS; Mayo Clinic). Imaging before removing any unexplained deep or growing lump, and specialist-planned biopsy, are the established safeguards.

How fast does soft tissue sarcoma progress?

It depends mainly on grade. High-grade tumors divide quickly, can enlarge over weeks to months and are more likely to have spread microscopically before diagnosis, which is why their follow-up is most intense early. Low-grade tumors may change little over years and relapse late, if at all (ESMO-EURACAN-GENTURIS guideline). No source can give a per-week growth rate for an individual; a rapidly enlarging lump simply warrants prompt assessment.

How fast does sarcoma spread to the lungs, and how is it found?

There is no fixed speed; spread to the lungs, when it happens, is most likely within the first two to three years after treatment for high-grade tumors, which is why chest imaging is scheduled every few months in that window (ESMO-EURACAN-GENTURIS guideline). Lung deposits are usually silent until large, so they are found on scheduled CT or X-ray rather than through symptoms.

Do I need a chest CT or is a chest X-ray enough?

Either is accepted in the guideline. CT detects smaller nodules but uses considerably more radiation; X-ray is simpler and lower dose (ESMO-EURACAN-GENTURIS guideline). Many teams choose CT for high-grade tumors and the highest-risk early years, and X-ray for low-grade tumors or later follow-up. The right choice is individual and worth asking your team to explain.

How long does sarcoma follow-up last?

Usually at least five years of scheduled visits, then annual checks that many teams continue long-term rather than ending abruptly. The guideline suggests high-grade tumors are seen every 3–4 months for 2–3 years, twice yearly to year five, then yearly; low-grade tumors every 4–6 months for 3–5 years, then yearly (ESMO-EURACAN-GENTURIS guideline). Some subtypes relapse late, which supports continuing annual review.

What does sarcoma recurrence after surgery feel like?

Local recurrence often presents as a new firm lump at or near the scar, sometimes with new or changing pain, swelling or numbness. Lung recurrence usually causes no symptoms until advanced, occasionally a persistent cough or breathlessness (NHS; Mayo Clinic). Familiar scar aching that fluctuates is common after surgery and radiotherapy; a new, growing or progressive change is what should prompt a call to your team.

Will I have an MRI at every follow-up visit?

Not necessarily. Local imaging frequency depends on depth, site, margins and how easily the area can be examined by hand. Many teams obtain a baseline MRI some weeks to months after treatment, then repeat it at intervals or when examination raises a question, sometimes using ultrasound for superficial sites (ESMO-EURACAN-GENTURIS guideline). Chest imaging tends to be the more regular fixture.

Can I stop follow-up if my scans have been clear for two years?

Guideline schedules deliberately continue beyond two years because a meaningful share of recurrences, particularly in low-grade and certain subtypes, appear later, and because lung relapse is usually silent (ESMO-EURACAN-GENTURIS guideline). Two clear years typically allow intervals to lengthen rather than end. Any change to your schedule should be agreed with your treating team, not made on your own.

References

• Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up (PubMed)
• Soft tissue sarcoma (NHS)
• Soft Tissue Sarcoma (MedlinePlus)

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.